Vaccinating the world’s population quickly in a pandemic has enormous health and economic benefits. We analyze the problem faced by governments in determining the scale and structure of procurement for vaccines. We analyze alternative approaches to procurement, arguing that buyers should directly fund manufacturing capacity and shoulder most of the risk of failure, while maintaining some direct incentives for speed. We analyzed the optimal portfolio of vaccine investments for countries with different characteristics as well as the implications for international cooperation. Our analysis, considered in light of the experience of 2020, suggests lessons for future pandemics. 

More on this topic

BFI Working Paper·Feb 4, 2025

Local GDP Estimates Around the World

Esteban Rossi-Hansberg and Jialing Zhang
Topics: COVID-19, Economic Mobility & Poverty
BFI Working Paper·Jan 22, 2025

Network Rewiring and Spatial Targeting: Optimal Disease Mitigation in Multilayer Social Networks

Ozan Candogan, Michael D. König, Kieran Marray, and Frank W. Takes
Topics: Health care
BFI Working Paper·Jan 21, 2025

Disease, Disparities, and Development: Evidence from Chagas Disease Control in Brazil

Jon Denton-Schneider and Eduardo Montero
Topics: Development Economics, Health care